Company

About

ALR Technologies

ALR Technologies

New York, US

ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with diabetes. ALRT has developed the FDA-cleared Health-e-Connect System which uploads the data from blood glucose meters onto a secure website where clinicians and Diabetes Care Facilitators can better monitor and coordinate the care of diabetes patients. ALRT's system goal is to assist patients to adhere to their care plan, improving the quality of diabetes care and making such care more cost effective to providers

Ascertain

Ascertain

New York, New York, United States

Ascertain, a healthcare technology company empowering care teams with AI, helps health systems, payers, and independent provider groups streamline operations and reduce administrative burden. Customers can either deploy Ascertain Automate, an enterprise software platform that uses agentic AI to automate high-volume administrative workflows, or engage Ascertain's tech-enabled services, outsourcing entire workflows to Ascertain's team, which operates the software on their behalf. From prior authorization and eligibility checks to discharge planning and patient scheduling, Ascertain's AI agents navigate complex systems, interpret unstructured data, and integrate across fragmented platforms — enabling faster throughput, lower costs, and more time for patient care. Ascertain was launched by Northwell Holdings, the for-profit investment arm of Northwell Health, and Aegis Ventures.

BioReference Laboratories (Opko Health)

BioReference Laboratories (Opko Health)

Albertson, New York, United States

For more than four decades, BioReference has built a legacy based on scientific excellence, innovation and world-class service in laboratory testing solutions. Amidst a tidal wave of change in healthcare in recent years, BioReference has evolved, adding significant services and solutions aimed at addressing the needs of today’s customers. Laboratory testing remains the cornerstone to the services we provide. As we challenge the limits of specialty diagnostics, we are making strategic investments to continue drive innovation and cultivate a unique customer experience, as well as expanding our reach to match the dynamic needs of an ever-changing healthcare system. BioReference offers scientific expertise and laboratory innovation in oncology, urology, and women’s health. Our organization provides credible and tailored solutions for a wide spectrum of customers and patients, including medical practices small and large, hospitals and health systems, correctional institutions, government agencies, educational systems, sport leagues, travel and leisure industries, and retail markets. In addition to an extensive test menu with 99% of tests performed in-house, BioReference’s differentiated offerings include large-scale health screening programs, on-demand mobile phlebotomy, and transformative business solutions that optimize laboratory testing and management. BioReference is part of OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Headquartered in Elmwood Park, New Jersey, BioReference operates 10 laboratory facilities around the country, is in-network with the largest health plans in the United States, and serves over 19 million patients annually.

Click Therapeutics

Click Therapeutics

New York, New York, United States

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. Digital therapeutics under development on our platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, cardiology and immunology. Consistently named a best place to work, we foster an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in our mission to provide patients everywhere access to safe and effective prescription digital therapeutics. NOTE: Fake job advertisements and offers are increasingly appearing on the internet. If you have encountered a job posting or have been approached with a job offer that you suspect may be fraudulent, we strongly recommend you do not respond and report it to the Federal Trade Commission and to recruitment@clicktherapeutics.com. Other than your email address or telephone number, which you may provide via a job application portal, Click Therapeutics will never ask you to provide personally identifiable information about yourself (such as a Social Security Number or Driver’s License Number) via a messaging application.

Koneksa Health

Koneksa Health

New York, New York, United States

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

MindMed

MindMed

New York, United States

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

One Drop

One Drop

166 Mercer St, New York, 10012, US

One Drop is a precision health company combining continuous diagnostics, predictive analytics and machine learning in an award-winning digital solution to deliver cost-saving outcomes for people living with diabetes and other chronic conditions. The goal: empower everyone to take proactive action for better health, peak performance, and more fulfilling lives.

Oshi Health

Oshi Health

New York. New York, United States

Oshi Health is the first and only virtual GI center of excellence - setting a new standard for life-changing digestive healthcare - delivering proven care models adapted to scale to help members lasting symptom control and drive savings through reduced avoidable medical spend. As an in-network provider through the nation’s leading health plans, Oshi provides total GI care - covering the full spectrum of GI symptoms and conditions from diagnosis to treatment through a multidisciplinary team of GI specialists, including dietary and behavioral health support.

PAVmed Inc.

PAVmed Inc.

60 E 42nd St, New York, 10165, US

PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.

Remepy

Remepy

New York, US

Remepy is Pioneering Hybrid Drugs™. Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities. Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities. The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.